Category: Uncategorized

Last Wednesday, the Alcalá de Henares plant received an institutional visit from the Mayor of Alcalá de Henares, Judith Piquet, accompanied by the Councillor for Economic Development and Employment, Antonio Peñalver; the Councillor for Health, Teófilo Lozano; the President of AEDHE, Laly Escudero; and the Manager of EPE Alcalá Desarrollo, Manuel García. With this visit, the municipal team was able to learn about the Group’s activity, as well as the plant’s new projects.

During their tour of the facilities, they were accompanied by ROVI’s Vice-President and General Manager of Industrial Operations and Finance, Javier López-Belmonte, the Director of the Industrial Area, Miguel Ángel Ortega, the Plant Manager, Pilar García-Morato, and the Corporate Director of Engineering, José Cristóbal.

The Alcalá de Henares plant employs more than 500 workers and houses not only production lines specialising in the manufacture of oral forms and the packaging of injectable solids, but also one of the company’s research and development centres. In recent months, ROVI has made a series of investments to expand industrial capacities. It is currently constructing a building to house new production lines that will be operational by 2025.

At ROVI we are committed to the environment, safety, health and physical and emotional well-being at work. As part of this commitment, we work every day on the basis of two management systems:

Environmental management system

We are based on a model whose pillars are the sustainable use of resources, energy efficiency and the implementation of the circular economy in our processes.

Health and safety management system

Focusing on technological innovation to eliminate hazards and reduce risks in the workplace.

Our commitment is known and disseminated to all interested parties through the Integrated Policy. This is why ROVI sets out its principles in terms of safety, health and the environment in:

OUR COMMITMENT GOES BEYOND WHAT IS REQUIRED. Not only do we comply with national and international legal requirements, but we also work to develop the concept of sustainable development throughout our value chain.

TO BE THE BEST. We optimise the use of natural resources and analyse risks in order to develop an efficient model of safety, health and environment.

CONTINUOUS IMPROVEMENT. We are committed to being better every day, defining objectives and goals that ensure a more sustainable future, incorporating new technologies and practices into our processes.

Last Sunday, the ROVI Team went out for a run, ready to break down walls with their running shoes. Specifically, the wall of stigma and discrimination suffered by people with mental health problems. And there is no better event than the Race for Mental Health, organised by the Fundación Manantial, to highlight the importance of social and occupational inclusion for people suffering from these pathologies.

In this year’s edition, setting a new record for participation, nearly 200 ROVI employees set out to run through the centre of Madrid, accompanied by more than 3,000 runners. The route, which varied between 10, 5 and 2.8 km depending on the mode, took the participants through a circuit that started in the Parque del Oeste, crossed Plaza de España to the Royal Palace and turned around leaving Colón behind.

ROVI smashed the record for the number of participants in the last event of the year, the Companies Race 2023. With 101 employees registered in 31 teams, Team ROVI almost tripled the number of runners compared to the previous year.

A race with the Madrid Skyline as a backdrop

Starting and finishing in San Juan de la Cruz Square, the race ran along the Castellana, passing through Nuevos Ministerios, the Santiago Bernabéu stadium and, for the long runners, Colón Square. A route with two modalities (6.5 km and 10 km) that brought together 17,000 runners, belonging to more than a thousand companies. It was a celebration of health and physical exercise.

Do you want to know how your colleagues did?

Don’t miss the video of the race.

Make your savings profitable!

ROVI employees can take advantage of special offers when opening interest-bearing accounts and deposits at Banco Cooperativo Español:

• Enjoy the conditions of the Remunerated Account: Open an account with the amount you want in exchange for remuneration at a fixed interest rate.
• Special offer for opening a Fixed Term Deposit: Deposit the amount you want for six months or one year in exchange for a fixed interest rate.

Working at ROVI has its advantages

For more information, please consult the document below:

Laboratorios Farmacéuticos ROVI announces its financial results for the first nine months of 2023. The company closed the period with operating revenue of 594.9 million euros, EBITDA of 171.2 million euros and a net profit of 118.8 million euros.

The CDMO business, which is one of the pillars of ROVI’s business strategy, showed a 7% increase on the first nine months of 2022, totalling 287.6 million euros.

ROVI’s injectables manufacturing plants in Madrid, San Sebastián de los Reyes and Alcalá de Henares were approved by the FDA for the fill-and-finish of syringes with the messenger RNA COVID-19 vaccine. Thus, ROVI also expects to produce Moderna vaccines for supply in the United States.

Heparin division sales (low-molecular-weight and other heparins) dropped 10% to 181.7 million euros in the first nine months of 2023. This was due to the difference between the increase in the orders placed by partners in 2022 related to the treatment for COVID-19 and the lower volume of orders from partners in 2023.

Risperidone ISM® sales evolved favourably and totalled 9 million euros. This product showed growth of 27% in the third quarter of the year in comparison with the second quarter of 2023.

R&D investment rose to 16.5 million euros and was mainly linked to development of the phase I of Letrozole LEBE and the development of phase I of the new three-monthly formulation of Risperidone ISM®.

Regarding the process for marketing authorisation for Risperidone ISM® in the United States, the FDA has notified ROVI of the new user fee goal data, which will be 29 March 2024.

ROVI is again raising its operating revenue guidance for 2023 from a high-single-digit percentage decrease on 2022 to stable sales.

For 2024, ROVI expects its operating revenue to decrease by a mid-teen percentage in comparison with 2023. Notwithstanding, this guidance depends on factors the impact of which is difficult to estimate at present, such as:

• -Evolution of the demand and production in the 2024 COVID-19 vaccination campaign, since the 2023 campaign is still in progress;
• -Potentially obtaining new customers in the CDMO area, with the resulting impact on sales; and
• Potential sales of Risperidone ISM in the United States once it has received marketing authorisation from the FDA.

Join the ROVI’s Team and take part with your colleagues and family members in the Fundación También charity race.

The funds raised will go to the foundation’s sports programme, which works for the inclusion of people with disabilities and promotes education in values through sport.

• When: 5 November
• Where: Valdebebas – Madrid
• Categories: 1km, 5km and 10km

Register HERE
You have until 19 October

For the second year running, ROVI has obtained the best ranking in the pharmaceutical industry category in the world rating of environmental, social and corporate governance (ESG) risks drawn up by Sustainalytics, a leading independent ESG research, rating and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. ROVI has revalidated its first place among 431 companies rated in the pharmaceutical industry group and remains in 22nd place among a total of 895 companies rated in the entire sector, which includes “biotechnology companies, pharmaceutical laboratories and laboratory equipment companies.”

In the rating process, Sustainalytics has analysed the company’s performance in sustainability aspects considered material in the pharmaceutical sector, highlighting ROVI’s sound management of ESG risks related to product quality and safety, corporate governance, business ethics, human capital, the fight against climate change and anti-corruption and anti-bribery practices. ROVI has obtained a higher-than-average score in areas such as the board’s involvement in the company’s environmental and social aspects, implementation of the environmental policy and a sound quality and safety programme for products and services, as well as the integration of ethical practices into all tiers of the organisation.

You may consult ROVI’s rating on this link: https://www.rovi.es/sites/default/files/laboratorios_farmaceuticos_rovi_sa_riskratingssummaryreport_08_03_2023.pdf

Commitment to sustainability

In 2022, ROVI approved its ESG Master Plan 2023-2025, a document that sets out 19 strategic ESG goals. With a three-year horizon, the Group has established a roadmap for attaining the Sustainable Development Goals (SDGs) of the United Nations Agenda 2030, with which ROVI, as a member of the Global Compact, is aligned.

The Group focuses its action on five priority areas:

– Becoming a leader in governance committed to sustainability.

– Commitment to sustainable management to combat the global environmental challenges: fight against climate change, promotion of the circular economy and efficient water management.

– Positioning itself as a key player in caring for persons and integrating specialised and diverse talent.

– Promoting responsible management of the supply chain, ensuring ethical and environmental standards in each one of its links.

– Promoting R&D&I activities by establishing partnerships with key players.

30 years is not an anniversary every day and the ROVI Team could not miss this very special edition of the Descenso del Sella Adaptado. Organised by the Federation for People with Disabilities of the Principality of Asturias, the competition was attended by 142 paddlers, 56 of whom were people with disabilities.

The 11 ROVI volunteers were able to cover the 16 km of the descent in a double canoe with one of the members of the Fundación También. The event ran from the Canoeing School in Arriondas to the Feve bridge in Llovio (Ribadesella), with the last 5 km being of a sporting nature.

“The experience in this volunteering has been incredible. Participating in this edition has allowed me to meet great fighters and examples of self-improvement. Being able to paddle with my canoeing partner Celia is one of the most beautiful gifts I have taken with me, getting this award thanks to our efforts together”, says Sandra Sánchez-Contador, one of the volunteers of this edition, awarded with the 3rd place in the female category.

We’d like to share with you all the ROVI Team’s experience in a video.

ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States and reports that the United States Food and Drug Administration (FDA) has issued a Complete Response Letter. In this letter, the FDA informs ROVI that it considers the responses to the evaluation of the Risvan® dossier to be complete and makes no additional observations.

Likewise, the letter states that ROVI must close the observations made by the FDA during its inspection in May 2023. ROVI will submit a response to reinitiate the procedure providing details of the responses that have already been filed. ROVI will then await a further notification from the FDA with the estimated User Fee Goal Date for the closure of the procedure, which is expected to be in February 2024.

Furthermore, there are no observations that have not yet been resolved by ROVI’s suppliers.

Therefore, ROVI will continue to report on the milestones deemed significant in the process to obtain authorisation of Risvan® from the FDA.